CAS NO: | 1429239-98-4 |
包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cas No. | 1429239-98-4 |
别名 | 1-(2,4-二氯苯基)-N-1-哌啶基-4-[[(1-吡咯烷基磺酰基)氨基]甲基]-5-[5-[2-[4-(三氟甲基)苯基]乙炔基]-2-噻吩基]-1H-吡唑-3-甲酰胺,BPRCB1184 |
Canonical SMILES | ClC1=CC(Cl)=CC=C1N2C(C3=CC=C(C#CC4=CC=C(C(F)(F)F)C=C4)S3)=C(CNS(=O)(N5CCCC5)=O)C(C(NN6CCCCC6)=O)=N2 |
分子式 | C33H31Cl2F3N6O3S2 |
分子量 | 751.67 |
溶解度 | DMSO: 125 mg/mL (166.30 mM) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | CB1-IN-1 is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.IC50 value: 0.3 nM (Ki, CB1R) 21 nM (Ki, CB2R)Target: CB1Rin vivo: CB1-IN-1 is a novel peripherally restricted cannabinoid 1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice. CB1-IN-1 has great potential to ameliorate this related metabolic syndrome. [1]. Chang CP, et al. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor anta |